21 of 21 therapies
| Indications | Biosimilars | |||||
|---|---|---|---|---|---|---|
Adbry tralokinumab-ldrm | IL-13 | injection | Atopic derm | no | none | — |
Bimzelx bimekizumab-bkzx | IL-17A / IL-17F | injection | PsoriasisHS | required | 3 tests | — |
Cibinqo abrocitinib | JAK1 | oral | Atopic derm | required | 6 tests | — |
Cimzia certolizumab pegol | TNF | injection | Psoriasis | required | 5 tests | — |
Cosentyx secukinumab | IL-17A | injection | PsoriasisHS | required | 3 tests | — |
Dupixent dupilumab | IL-4Rα (IL-4/IL-13) | injection | Atopic dermPrurigo nod.Chronic urticaria | no | none | — |
Ebglyss lebrikizumab-lbkz | IL-13 | injection | Atopic derm | no | none | — |
Humira adalimumab | TNF | injection | PsoriasisHS | required | 5 tests | 10 available |
Icotyde icotrokinra | IL-23 receptor (oral peptide) | oral | Psoriasis | no | 3 tests | — |
Ilumya tildrakizumab-asmn | IL-23 | injection | Psoriasis | required | 3 tests | — |
Litfulo ritlecitinib | JAK3 / TEC | oral | Alopecia | required | 6 tests | — |
Nemluvio nemolizumab-ilto | IL-31RA | injection | Atopic dermPrurigo nod. | no | none | — |
Olumiant baricitinib | JAK1 / JAK2 | oral | Alopecia | required | 6 tests | — |
Otezla apremilast | PDE4 | oral | Psoriasis | no | none | — |
Rinvoq upadacitinib | JAK1 | oral | Atopic derm | required | 6 tests | — |
Skyrizi risankizumab-rzaa | IL-23 | injection | Psoriasis | required | 3 tests | — |
Sotyktu deucravacitinib | TYK2 | oral | Psoriasis | required | 3 tests | — |
Stelara ustekinumab | IL-12 / IL-23 | injection | Psoriasis | required | 3 tests | 8 available |
Taltz ixekizumab | IL-17A | injection | Psoriasis | required | 3 tests | — |
Tremfya guselkumab | IL-23 | injection | Psoriasis | required | 3 tests | — |
Xolair omalizumab | IgE | injection | Chronic urticaria | no | none | — |
Usage events this tool reports
0 events
No events yet.